Enhanced Gel Ophthalmic Formulations of Pilocarpine and Brimonidine Compounds for Presbyopia Treatment

This inventive concept improves the original gel ophthalmic formulations of pilocarpine and brimonidine compounds by introducing novel enhancements that address limitations of the original patent, providing better efficacy, safety, and patient comfort in presbyopia treatment.

The original patent disclosed gel ophthalmic formulations of pilocarpine and brimonidine compounds for treating presbyopia. However, these formulations had limitations, such as inconsistent dosing, pH-dependent degradation, and potential ocular side effects. This new inventive concept addresses these limitations by introducing precision dosing devices, pH-adjusting excipients, novel buffer systems, and soothing agents, enhancing the overall efficacy and safety of the formulations.

The new inventive concept comprises four key enhancements to the original gel ophthalmic formulations. Firstly, a precision dosing device ensures accurate and consistent dosing, reducing the risk of under- or over-dosing. Secondly, a pH-adjusting excipient optimizes the pH range for maximum bioavailability of the active pharmaceutical ingredients. Thirdly, a novel buffer system minimizes the pH-dependent degradation of the pilocarpine and brimonidine compounds. Lastly, a soothing agent is incorporated to reduce irritation and discomfort associated with the use of these compounds. These enhancements work in synergy to provide better efficacy, safety, and patient comfort in presbyopia treatment.

The new claims introduce several novel and non-obvious features compared to the original patent, including the use of precision dosing devices, pH-adjusting excipients, novel buffer systems, and soothing agents. These features provide a significant improvement over the original formulations, addressing specific limitations and providing better outcomes for patients.

Alternative embodiments of the inventive concept could include using different types of precision dosing devices, such as micro-needles or iontophoresis systems. Additionally, various pH-adjusting excipients or buffer systems could be employed to optimize the formulation's performance. Furthermore, different soothing agents or combinations of agents could be used to minimize ocular side effects.

The enhanced gel ophthalmic formulations of pilocarpine and brimonidine compounds have significant commercial potential in the ophthalmic industry, particularly in the treatment of presbyopia. The market for presbyopia treatment is growing rapidly, driven by an aging population and increasing demand for effective and safe treatments. This inventive concept addresses a specific need in the market, providing a competitive advantage for companies that develop and commercialize these formulations.